Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer

AACR 2024

5 - 10 Apr 2024

Published: 29 Apr 2024

Views: 84

Rating:

Save

Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel

Professor Jair Bar speaks to ecancer about the KEYNOTE-782 trial.

This trial aimed to determine the correlation between blood tumour mutational burden (bTMB) and the efficacy of first-line pembrolizumab plus chemotherapy in patients with non-small cell lung cancer (NSCLC).

The study's results showed that the adverse events observed were consistent with the known safety profile of first-line pembrolizumab plus chemotherapy in NSCLC.

However, the baseline bTMB did not show any evidence of being associated with efficacy.

Related Videos

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy

Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

More from ecancer